IL10 and metabolic dysfunction-associated steatotic liver disease: To assess physiological relevance of this finding, we analyzed published liver transcriptomic datasets spanning patients with HCV infection with and without antiviral therapy and cohorts with metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD).[24], [25], [26] Hepatic IL10 transcripts increased after anti-HCV treatment and declined with disease progression in MASLD and ALD (Fig. S8E), consistent with a possible role for IL-10 in promoting HSC reversion.